Vas Narasimhan, Novartis CEO (Simon Dawson/Bloomberg via Getty Images)
October 29, 2021 04:42 PM EDT
R&D

Two decades af­ter Gleevec ap­proval, No­var­tis scores new CML OK for 'wild card' STAMP in­hibitor

Amber Tong

One of the lat­est ad­di­tions to Vas Narasimhan’s “wild card” drug list has de­liv­ered.

Scem­blix, as as­ci­minib will be mar­ket­ed, will be the first …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

As blue­bird projects more com­mer­cial de­mand, the biotech con­tin­ues to seek cash

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times